Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
After ZW171's exit, ZW251 enters the clinic.
While Cogent joins the FGFR party.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Just when investors thought things couldn't get any worse, they do.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
